New drug avoids treatment problem for hepatitis C patients

10/31/2006 | HealthDay News

Researchers say hepatitis C patients with cirrhosis and low platelet levels can take standard antiviral medications if they also use the new drug eltrombopag. Two common drugs, ribavirin and pegylated interferon, further reduce platelet levels in patients, but eltrombopag counters that effect.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC